Adherence to disease-modifying therapies and attitudes regarding disease in patients with multiple sclerosis

Ožura, Ana; Kovač, Lea; Šega, Saša

doi:10.1016/j.clineuro.2013.09.013

Cited by 13 publications

(21 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“… 13 Moreover, in studies using the index of proportion of days covered (calculated by dividing the number of days of DMT supplied by the number of days of observation), the percentage of adherents ranged from 58.58% for injection patients and 61.39% for oral patients 12 to 76% after the first year of treatment. 18 In the present study, the percentage of adherents was 76.5%, which is similar to the results obtained by other researchers 5 – 7 , 15 who used a self-report questionnaire to determine the number of adherent patients by adopting the criterion of assessing all doses in the previous month.…”

Section: Discussionsupporting

confidence: 90%

“…With respect to sociodemographic variables, the analysis showed no statistically significant differences between adherent and nonadherent patients, which is consistent with the results of Ožura et al 7 and Wicks et al 10 However, according to Burks et al, 12 women are 24% less likely to be adherent than men. Moreover, Higuera et al 21 found that women had a 5.5% lower probability of being adherent than men.…”

Section: Discussionsupporting

confidence: 88%

“…In previous studies that used the MS-TAQ instrument, patients were identified as nonadherent if they missed one or more dose in the 28 days prior to completing the survey 10 or if they missed at least 25% of the chosen DMT doses, that is, if they missed ≥1 injection of Avonex; ≥3 injections of Rebif, Betaferon, Extavia, or Copaxone 40 mg; or ≥7 injections of Copaxone 20 mg. 7 In this study, nonadherent patients also included those taking Tecfidera who missed two or more tablets (the first criterion) or missed more than 14 tablets in one month (the second criterion).…”

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Adherence to disease-modifying therapies in patients with multiple sclerosis

Kołtuniuk¹,

Rosińczuk²

2018

PPA

View full text Add to dashboard Cite

BackgroundMultiple sclerosis (MS) is a chronic, inflammatory progressive demyelinating disease of the central nervous system. MS is one of the main causes of disability among young adults, and its management is a serious challenge for the healthcare system.PurposeThe main purpose of this study was to examine adherence to first-line disease-modifying therapy (DMT) in MS patients using the self-report Multiple Sclerosis Treatment Adherence Questionnaire (MS-TAQ).Materials and methodsThe participants consisted of 226 MS patients (166 women and 60 men) who were treated with first-line immunomodulatory DMT. This study used a questionnaire designed by the authors, which contained questions about sociodemographic data, and the Polish version of the MS-TAQ.ResultsThe overall adherence was 76.5% according to the first criterion (missed ≥1 injection or tablet). There were no statistically significant differences due to sociodemographic variables between adherent and nonadherent patients. However, patients taking Avonex® significantly more often belonged to the adherent group (P=0.042). The most frequently mentioned reasons why nonadherent patients forget to take the drug included the following: too busy in their daily activities, indisposition to take the drug, unwillingness to take the drug, interference with daily activities, and dissatisfaction with the drug. The degree of adherence among MS patients treated with immunomodulatory drugs is high; however, some patients do not take medications regularly.ConclusionDue to the utility of the MS-TAQ, the caregivers of MS patients are able to quickly and easily assess the occurrence of side effects, ways to cope with them, and the occurrence of barriers to taking medication.

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Discussionsupporting

confidence: 88%

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Adherence to disease-modifying therapies in patients with multiple sclerosis

Kołtuniuk¹,

Rosińczuk²

2018

PPA

View full text Add to dashboard Cite

show abstract

“…The results of a recent study from Germany which included more than 50,000 patients treated with injectables showed that less than 40% of them were adherent to the therapy [7]. The data from our center (N=299) are not so discouraging with about 80% adherence rate [8].…”

Section: Practical Problemsmentioning

confidence: 91%

My MRI worsened but I didn't. Should I change my disease-modifying treatment?

Rot¹

2016

IJCNMH

View full text Add to dashboard Cite

It is imperative to recognize multiple sclerosis (MS) patients with high risk of disability progression as soon as possible and offer them more potent treatment.Data about the influence of early conventional MRI parameter worsening (without clinical progression or relapses) on early or late disability in treated MS patients are available mainly for interferons beta. Some of the studies showed that the development of new T2 or Gd enhancing lesions in the first year of interferon beta treatment predicted second and third year disease activity or worse late clinical outcome, but some of the studies were negative. The first-year MRI activity was not associated with clinical worsening of the disease in the next two years in patients treated with glatiramer acetate. There are no data which would indicate that the MRI-only worsening in patients treated with the oral drugs or monoclonal antibodies predicts poor outcome.There are many caveats which also need to be taken into account when considering an individual patient with the MRI-only worsening for escalation of therapy such as adherence to the injectables, presence of neutralizing antibodies, large interrater variability for comparative MRI data and adverse effects of the second-line drugs. Therefore a close clinical and MRI follow-up of patients with the MRI-only worsening is appropriate but escalation should be given only to those with more realistic risk of a poor prognosis. AbstractMRI worsenig and prognosis of multiple sclerosis 2 ARC Publishing

show abstract

“…Another widely discussed issue related to the therapy of any first-line injectable drugs is the adherence of MS patients to DMD treatment which relying on different published data, varies from 70-75% for interferon beta [23] to 49% for glatiramer acetate [24]. Among the most common reasons for patient refusal from the prescribed treatment are the unwillingness to use injection forms (20,4-21,1%) and complications related to the subcutaneous and intramuscular drug injections (32-32,9%) [22].…”

Section: Budget Impact Analysis Of Teriflunomide (Aubagio) Proposed Imentioning

confidence: 99%

Budget impact analysis of teriflunomide (aubagio) proposed inclusion into the programme ‘7 high-cost nosologies’ on the budgets of RF federal and regional public authorities in the field of healthcare to ensure treatment of multiple sclerosis patients

Evdoshenko¹,

Solodun²,

Bashlakova³

et al. 2016

Pharmacoeconom T&P

View full text Add to dashboard Cite

Objective: Budget impact analysis of teriflunomide inclusion as first-line disease modifying drugs (DMD) therapy in the List to ensure patients with relapsing-remitting multiple sclerosis (RRMS) within the programme '7 high-cost nosologies' on the budgets of Russian Federation (RF) federal and regional public authorities in the field of health care. Methods 132,89 RUB in 2017 and 16 893 811 827,74 RUB in 2018. Inclusion of teriflunomide is connected with total costs for patient management equal to 14 908 830 663,19 RUB (2017) and 16 406 368 100,05 RUB (2018). Conclusion:Inclusion of teriflunomide into the programme '7 high-cost nosologies' will cause total cost saving for budget of federal authorities of the RF in the field of healthcare of 268 666 174,08 RUB and 517 023 249,99 RUB in 2017 and 2018, respectively, and total costs of federal and regional authorities of the RF in the field of healthcare for provision of patients with multiple sclerosis will be reduced by 239 237 469,70 RUB in 2017 and by 487 443 727,70 RUB in 2018.

show abstract

Adherence to disease-modifying therapies and attitudes regarding disease in patients with multiple sclerosis

Cited by 13 publications

References 26 publications

Adherence to disease-modifying therapies in patients with multiple sclerosis

Adherence to disease-modifying therapies in patients with multiple sclerosis

My MRI worsened but I didn't. Should I change my disease-modifying treatment?

Budget impact analysis of teriflunomide (aubagio) proposed inclusion into the programme ‘7 high-cost nosologies’ on the budgets of RF federal and regional public authorities in the field of healthcare to ensure treatment of multiple sclerosis patients

Contact Info

Product

Resources

About